Abstract
Background
To introduce a case of Vogt–Koyanagi–Harada (VKH) disease in which the serous retinal detachment (SRD), refractory to the systemic steroid therapy, was resolved in a short time after an intravitreal injection of bevacizumab.
Methods
Interventional case report to show the effect of bevacizumab for the SRD in a VKH patient.
Results
A 42-year-old woman, diagnosed with VKH disease, showed decreased visual acuities and multiple SRDs in both eyes. The best-corrected visual acuity (BCVA) was FC 30 cm in both eyes. On optical coherence tomography (OCT), multiple SRDs were confirmed. On OCT, the height of SRD in the central fovea area was 1119 μm in the right eye and 1151 μm in the left eye. After high-dose steroid treatment for 5 weeks, the SRD in the left eye was completely resolved, however, the SRD in the right eye was persisted. At the time, the height of SRD in the right eye was 884 μm and the BCVA was 0.1. For the treatment of persistent SRD causing a decreased visual acuity despite a long-term high-dose course of systemic steroid therapy, an intravitreal injection of 1.25 mg bevacizumab was performed for the right eye, following an informed consent. One week later, there was fast and complete reabsorption of multiple SRDs in the right eye. The retinal thickness in the foveal area was measured to be 189μm by OCT and the BCVA was improved to 0.7.
Discussion
An intravitreal injection of bevacizumab combined with systemic steroid in VKH is expected to shorten the time for the persistent presence of SRD and to prevent the permanent visual impairment.
This is a preview of subscription content, log in via an institution to check access.
References
Nussenblatt RB (2004) Vogt–Koyanagi–Harada syndrome. In: Nussenblatt RB, Whitcup SM (eds) Uveitis fundamentals and clinical practice, 3rd edn. CV Mosby, St. Louis, pp 324–338
Rodrigues EB, Farah ME, Maia M, Penha FM, Regatieri C, Melo GB, Pinheiro MM, Zanetti CR (2009) Therapeutic monoclonal antibodies in ophthalmology. Prog Retin Eye Res 28:117–144
Yamanaka E, Ohguro N, Yamamoto S, Nakagawa Y, Imoto Y, Tano Y (2002) Evaluation of pulse corticosteroid therapy for Vogt–Koyanagi–Harada disease assessed by optical coherence tomography. Am J Ophthalmol 134:454–456
Andrade RE, Muccioli C, Farah ME, Nussenblatt RB, Belfort R Jr (2004) Intravitreal triamcinolone in the treatment of serous retinal detachment in Vogt–Koyanagi–Harada syndrome. Am J Ophthalmol 137:572–574
Young S, Larkin G, Branley M, Lightman S (2001) Safety and efficacy of intravitreal triamcinolone for cystoid macular oedema in uveitis. Clin Experiment Ophthalmol 29:2–6
Cordero Coma M, Sobrin L, Onal S, Christen W, Foster CS (2007) Intravitreal bevacizumab for treatment of uveitic macular edema. Ophthalmology 114:1574–1579
Fine HF, Baffi J, Reed GF, Csaky KG, Nussenblatt RB (2001) Aqueous humor and plasma vascular endothelial growth factor in uveitis-associated cystoids macular edema. Am J Ophthalmol 132:794–796
Lott MN, Schiffman JC, Davis JL (2009) Bevacizumab in inflammatory eye disease. Am J Ophthalmol 149:711–717
Lim SJ, Roh MI, Kwon OW (2010) Intravitreal bevacizumab injection for central serous chorioretinopathy. Retina 30:100–106
Author information
Authors and Affiliations
Corresponding author
Additional information
The authors have no financial interest in any products or methods shown in this paper.
Rights and permissions
About this article
Cite this article
Park, H.S., Nam, K.Y. & Kim, J.Y. Intravitreal bevacizumab injection for persistent serous retinal detachment associated with Vogt–Koyanagi–Harada disease. Graefes Arch Clin Exp Ophthalmol 249, 133–136 (2011). https://doi.org/10.1007/s00417-010-1477-8
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00417-010-1477-8